What is Third Arc Bio?
Third Arc Bio operates at the intersection of immunology and oncology, specializing in the design of multifunctional antibody medicines. The company focuses on modulating immune synapses to address complex challenges in solid tumors and inflammatory diseases. By integrating advanced discovery platforms with deep translational expertise, Third Arc Bio aims to deliver transformative biologic therapies that address significant unmet medical needs. Its market position is defined by a commitment to precision medicine and the development of novel therapeutic modalities that target the underlying mechanisms of disease progression.
How much funding has Third Arc Bio raised?
Third Arc Bio has raised a total of $217M across 2 funding rounds:
Series A
$165M
Series A
$52M
Series A (2024): $165M with participation from Vida Ventures, Hillhouse Investments, and Cormorant Asset Management Puerto Rico
Series A (2026): $52M led by Andreessen Horowitz
Key Investors in Third Arc Bio
Vida Ventures
A life sciences investment firm founded by scientists and entrepreneurs, focused on building and funding breakthroughs in biomedicine to advance transformative innovations.
Andreessen Horowitz
A prominent American venture capital firm that provides strategic backing to both early-stage startups and established growth companies across various technology and life science sectors.
Hillhouse Investments
A venture capital and private equity firm that provides essential financial support to high-growth companies, leveraging deep industry expertise to foster long-term value creation.
What's next for Third Arc Bio?
With the infusion of $52M, Third Arc Bio is poised to scale its clinical operations and expand its research capabilities. The strategic focus will likely center on the advancement of its lead candidates through human trials, while simultaneously refining its discovery engine to identify new targets within the immune synapse. As the company transitions into a more mature clinical-stage entity, the focus will shift toward data generation and potential partnerships that could validate its platform's efficacy. Investors are closely monitoring the firm's ability to translate its preclinical success into meaningful clinical outcomes, which will be the primary driver for future valuation growth and potential long-term commercialization efforts.
See full Third Arc Bio company page
